P73 Predictors of flares after glucocorticoid discontinuation in remitted patients with SLE

P73 Predictors of flares after glucocorticoid discontinuation in remitted patients with SLE

Bibliographic Details
Main Authors:	Andrea Doria, Margherita Zen, Luca Iaccarino, Filippo Vesentini, Federico Arru, Rosanna Somma, Noemi Merra, Cristina Cadore, Ilenia Gennaio, Claudio Cruciani
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2024-03-01
Series:	Lupus Science and Medicine

Similar Items

P72 Glucocorticoid discontinuation after remission achievement in not associated with an increased risk of flares
by: Andrea Doria, et al.
Published: (2024-03-01)

P26 In remitted SLE patients BAFF/BLyS serum levels measured at the time of immunosuppressant discontinuation are higher in patients with subsequent flares
by: Andrea Doria, et al.
Published: (2024-03-01)

P143 Efficacy of consultation before and during pregnancy on therapeutic adherence surveyed in a single-center cohort of patients with rheumatic disease
by: Andrea Doria, et al.
Published: (2024-03-01)

LP-069 Update of the epidemiology and mortality of juvenile onset SLE and pediatric SLE in Italy
by: Andrea Doria, et al.
Published: (2023-07-01)

P5 Patients with obstetric antiphospholipid syndrome have constitutively higher complement activation compared to healthy controls
by: Andrea Doria, et al.
Published: (2024-03-01)

P79 Clinical features and prevalence of late and very late onset systemic lupus erythematosus
by: Andrea Doria, et al.
Published: (2024-03-01)

Glucocorticoid discontinuation in patients with SLE with prior severe organ involvement: a single-center retrospective analysis
by: Masato Okada, et al.
Published: (2022-05-01)

Hormones, immune response, and pregnancy in healthy women and SLE patients.
by: M Zen, et al.
Published: (2010-04-01)

Clinical outcomes of patients with remitting ulcerative colitis after discontinuation of indigo naturalis
by: Fumie Shimada, et al.
Published: (2024-03-01)

18 Management of musculoskeletal involvement in SLE
by: Andrea Doria
Published: (2023-09-01)

P138 Pregnancy outcomes in SLE patients treated with belimumab: the Italian experience
by: Andrea Doria, et al.
Published: (2024-03-01)

LSO-021 Epidemiology and survival of SLE in the last decade: data from a large population-based study in northeastern Italy
by: Andrea Doria, et al.
Published: (2023-07-01)

Anti-dsDNA B-Cell ELISpot as a Monitoring and Flare Prediction Tool in SLE Patients
by: Albert Pérez-Isidro, et al.
Published: (2023-02-01)

PO.8.177 Low complement levels in the first trimester predict disease flare in SLE pregnancy: a network meta-analysis on 532 patients
by: L Andreoli, et al.
Published: (2022-10-01)

Low-dose IL-2 mitigates glucocorticoid-induced Treg impairment and promotes improvement of SLE
by: Haotian Zhou, et al.
Published: (2023-04-01)

Tapering and discontinuation of glucocorticoids in patients with rheumatoid arthritis treated with tofacitinib
by: Francesca Romana Spinelli, et al.
Published: (2023-09-01)

PO.3.73 Soluble CD200 concentration in serum is increased in SLE patients and correlates with anti-dsdna
by: M Limper, et al.
Published: (2022-10-01)

O21 Is SLE-DAS better than BILAG-2004 to identify severe SLE disease activity? Post-hoc analysis of 438 SLE patients from the anifrolumab clinical trials
by: Andrea Doria, et al.
Published: (2024-03-01)

Disease Flare after Discontinuation of Crizotinib in Anaplastic Lymphoma Kinase-Positive Lung Cancer
by: Yuka Kuriyama, et al.
Published: (2013-08-01)

Tapering glucocorticoids and risk of flare in rheumatoid arthritis on biological disease-modifying antirheumatic drugs (bDMARDs)
by: Giovanni Adami, et al.
Published: (2023-01-01)

Disentangling pharmacological and expectation effects in antidepressant discontinuation among patients with fully remitted major depressive disorder: study protocol of a randomized, open-hidden discontinuation trial
by: Carina Meißner, et al.
Published: (2023-06-01)

Not in our remit
Published: (2014)

SLE and alpha-SLE driven by Levy processes
by: Guan, Q, et al.
Published: (2008)

LO-018 Effect of COVID-19 infection on disease flares and herpes zoster reactivation in patients with SLE: a case-control study
by: Ling Yin Ho, et al.
Published: (2023-07-01)

Is it possible to discontinue glucocorticoids in rheumatoid arthritis with the use of synthetic disease-modifying antirheumatic drugs?
by: O. B. Iaremenko, et al.
Published: (2023-07-01)

P127 The SLE-DAS enables easy identification of SLE patients with moderate-to-severe disease activity and worse HR-QoL in the screening for SLE clinical trials: a post-hoc study in the phase 2 and 3 anifrolumab trials
by: Andrea Doria, et al.
Published: (2024-03-01)

O3 Physician experience influences glucocorticoid prescribing patterns in systemic lupus erythematosus (SLE): results from the LUPHPOS survey
by: Marta Mosca, et al.
Published: (2024-03-01)

1501 Enpatoran: preclinical evidence supporting glucocorticoid dose reduction and Phase II study design in patients with SLE and/or CLE (WILLOW)
by: Victoria P Werth, et al.
Published: (2022-12-01)

Severe flares are associated with a poorer health-related quality of life (HRQoL) in patients with SLE: data from the Almenara Lupus Cohort
by: Manuel Francisco Ugarte-Gil, et al.
Published: (2022-05-01)

LO-024 Association between severe non-adherence to hydroxychloroquine and SLE flares, damage, and mortality in 660 patients from the SLICC inception cohort
by: Joan T Merrill, et al.
Published: (2023-07-01)

A Retrospective Analysis of Real-World Discontinuation Rates with Delayed-Release Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis
by: Michelle Allan, et al.
Published: (2019-12-01)

ADE and SLE
by: Cardy, J
Published: (2007)

Risk factors of flare in patients with systemic lupus erythematosus after glucocorticoids withdrawal. A systematic review and meta-analysis
by: Wenhui Xie, et al.
Published: (2022-01-01)

LP-196 Low-dose IL-2 therapy in SLE: efficacy on organ involvement, response predictors and synergistic effects with glucocorticoid treatment
by: Zhanguo Li, et al.
Published: (2023-07-01)

LP-183 Enpatoran: preclinical evidence supporting glucocorticoid dose reduction and phase II study design in patients with SLE and/or CLE (WILLOW)
by: Victoria P Werth, et al.
Published: (2023-07-01)

PO.6.135 Enpatoran: preclinical evidence supporting glucocorticoid dose reduction and phase II study design in patients with SLE and/or CLE (WILLOW)
by: F Moreau, et al.
Published: (2022-10-01)

PO.5.104 Evaluation of traditional laboratory markers as predictors of renal flares: a post-hoc analysis of four phase iii clinical trials of SLE
by: A Gómez, et al.
Published: (2022-10-01)

To flare or not to flare: patients’ and rheumatologists’ perceptions on the on-flare retreatment strategy of rituximab in rheumatoid arthritis
by: Delphine Bertrand, et al.
Published: (2024-02-01)

Harmonic measure and SLE
by: Beliaev, D, et al.
Published: (2008)

SLE for theoretical physicists
by: Cardy, J
Published: (2005)